Compare Stocks

Enter up to five stock symbols separated by a comma or space (ex. BAC,WFC,JPM,LON:BARC).

Date Range:

	Interpace Biosciences	InVivo Therapeutics	Vivos	Arch Therapeutics	Obalon Therapeutics
Symbol	NASDAQ:IDXG	NASDAQ:NVIV	OTCMKTS:RDGL	OTCMKTS:ARTH	NASDAQ:OBLN
Price Information
Current Price	$8.10	$0.68	$0.08	$0.13	$3.32
52 Week Range	Buy	N/A	N/A	Buy	Buy
MarketRank™
Overall Score	1.5	0.7	0.0	1.2	0.5
Analysis Score	1.5	0.0	0.0	3.5	0.0
Community Score	2.9	2.8	0.0	2.4	2.4
Dividend Score	0.0	0.0	0.0	0.0	0.0
Ownership Score	2.5	0.0	0.0	0.0	0.0
Earnings & Valuation Score	0.6	0.6	0.0	0.0	0.0
Analyst Ratings
Consensus Recommendation	Buy	N/A	N/A	Buy	Buy
Consensus Price Target	$8.00	N/A	N/A	$1.38	N/A
% Upside from Price Target	-1.23% downside	N/A	N/A	974.22% upside	N/A
Trade Information
Market Cap	$33.24 million	$23.26 million	$26.45 million	$30.30 million	$33.27 million
Beta	1.23	1.9	2.88	0.11	-0.69
Average Volume	178,906	3,840,254	3,829,656	391,142	7,902,003
Sales & Book Value
Annual Revenue	$24.08 million	N/A	$10,000.00	N/A	$3.28 million
Price / Sales	1.38	N/A	2,645.08	N/A	10.14
Cashflow	N/A	N/A	N/A	N/A	N/A
Price / Cash	N/A	N/A	N/A	N/A	N/A
Book Value	$3.41 per share	$10.15 per share	($0.06) per share	($0.01) per share	$2.06 per share
Price / Book	2.38	N/A	-1.38	N/A	1.61
Profitability
Net Income	$-26,730,000.00	$-11,830,000.00	$-1,610,000.00	$-4,690,000.00	$-23,680,000.00
EPS	($5.58)	N/A	N/A	N/A	N/A
Trailing P/E Ratio	N/A	0.00	0.00	0.00	N/A
Forward P/E Ratio	N/A	∞	∞	N/A	∞
P/E Growth	N/A	N/A	N/A	N/A	N/A
Net Margins	-115.30%	N/A	N/A	N/A	-688.07%
Return on Equity (ROE)	-251.52%	-124.37%	N/A	N/A	-159.14%
Return on Assets (ROA)	-37.77%	-91.12%	-1,120.71%	-159.31%	-97.30%
Dividend
Annual Payout	N/A	N/A	N/A	N/A	N/A
Dividend Yield	N/A	N/A	N/A	N/A	N/A
Three-Year Dividend Growth	N/A	N/A	N/A	N/A	N/A
Payout Ratio	N/A	N/A	N/A	N/A	N/A
Years of Consecutive Dividend Growth	N/A	N/A	N/A	N/A	N/A
Debt
Debt-to-Equity Ratio	2.01%	N/A	N/A	N/A	0.07%
Current Ratio	1.62%	4.38%	0.06%	3.32%	1.79%
Quick Ratio	1.62%	4.38%	0.06%	1.82%	1.79%
Ownership Information
Institutional Ownership Percentage	17.13%	0.48%	0.08%	0.04%	28.00%
Insider Ownership Percentage	54.40%	0.58%	18.50%	12.16%	8.10%
Miscellaneous
Employees	152	6	1	7	2
Shares Outstanding	4.10 million	34.18 million	318.68 million	236.72 million	10.02 million
Next Earnings Date	6/24/2021 (Estimated)	N/A	6/29/2021 (Estimated)	5/18/2021 (Estimated)	6/18/2021 (Estimated)
Optionable	Not Optionable	Not Optionable	Not Optionable	Not Optionable	Optionable

Source	Headline
	Obalon Announces First Quarter 2021 Financial Results finance.yahoo.com - May 12 at 11:09 AM
	Obalon Therapeutics, Inc. Urges Stockholders to IMMEDIATELY Vote FOR All Proposals Related to the Merger with ReShape Lifesciences Inc dgap.de - May 11 at 11:17 PM
	Obalon TherapeuticsInc. (NASDAQ:OBLN) Jumps 30.45% in Recent Session, What Things You Absolutely Need To Know? stocksregister.com - May 11 at 1:17 PM
	Let’s Jump into the Obalon Therapeutics, Inc. (NASDAQ:OBLN) Stock Forecast marketingsentinel.com - May 10 at 5:12 PM
	Obalon Therapeutics, Inc. (NASDAQ:OBLN) Short Interest Update americanbankingnews.com - May 3 at 1:32 PM
	SHAREHOLDER ALERT: WeissLaw LLP Reminds BFTL, OBLN, FI, and BMTC Shareholders About Its Ongoing Investigations finance.yahoo.com - April 23 at 7:19 PM
	For Obalon Therapeutics Inc. [OBLN], Analyst sees a rise to $3. What next? dbtnews.com - April 21 at 2:11 PM
	Analysts think Obalon Therapeutics, Inc. (NASDAQ:OBLN) could rise 147.98% from current levels stocksregister.com - April 20 at 12:54 PM
	Obalon Therapeutics Inc (OBLN) investing.com - April 18 at 10:27 PM
	Obalon Announces Fourth Quarter and Full Year 2020 Financial Results finance.yahoo.com - March 12 at 7:24 PM
	OBLN Stock Price Increases Over 20% Pre-Market: Why It Happened pulse2.com - March 10 at 1:09 PM
	INVESTIGATION ALERT: Halper Sadeh LLP Investigates VIE, SMTX, NK, OBLN; Shareholders Are Encouraged to Contact the Firm finance.yahoo.com - February 2 at 2:20 PM
	SHAREHOLDER ALERT: Rigrodsky Law, P.A. Announces Investigation of Obalon Therapeutics, Inc. Merger apnews.com - January 25 at 2:44 PM
	Datavisor Global Digital Fraud Trends Report 2021 globalbankingandfinance.com - January 23 at 2:11 PM
	SHAREHOLDER ALERT: Monteverde & Associates PC Announces an Investigation of Obalon Therapeutics, Inc. - OBLN finance.yahoo.com - January 23 at 9:10 AM
	OBALON ALERT: Bragar Eagel & Squire, P.C. Investigates Sale of OBLN and Encourages Investors to Contact the Firm finance.yahoo.com - January 22 at 6:28 PM
	OBALON INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of Obalon Therapeutics, Inc. - OBLN businesswire.com - January 22 at 1:28 PM
	SHAREHOLDER ALERT: WeissLaw LLP Investigates Obalon Therapeutics, Inc. finance.yahoo.com - January 21 at 7:16 PM
	ROCE Insights For Obalon Therapeutics finance.yahoo.com - January 21 at 2:15 PM
	PFE/BNTX Covid Jab Neutralizes UK Strain, Pura Vida Ups Stake In OCX, Woodcock Is Interim FDA Chief nasdaq.com - January 21 at 2:48 AM
	ReShape and Obalon Merge in All-Stock Transaction mddionline.com - January 20 at 4:48 PM
	Obalon Surges 470% On ReShape Lifesciences Merger Agreement msn.com - January 20 at 4:48 PM
	Return On Capital Employed Overview: Obalon Therapeutics finance.yahoo.com - December 7 at 4:42 PM
	Why Is It Moving? Analyzing The Upward Movement in Obalon Therapeutics's Stock Today finance.yahoo.com - December 7 at 4:42 PM
	OBLN Stock: 11 Things to Know About Weight Loss Balloon Play Obalon Therapeutics feedproxy.google.com - December 7 at 12:41 PM

Date	Company	Brokerage	Action
4/15/2021	Interpace Biosciences	HC Wainwright	Boost Price Target
10/22/2020	Interpace Biosciences	Alliance Global Partners	Lower Price Target
4/24/2020	Interpace Biosciences	Maxim Group	Reiterated Rating
4/15/2020	Interpace Biosciences	Janney Montgomery Scott	Initiated Coverage
9/26/2019	Interpace Biosciences	Oppenheimer	Initiated Coverage
5/5/2021	Arch Therapeutics	Dawson James	Initiated Coverage
8/4/2020	Arch Therapeutics	LADENBURG THALM/SH SH	Reiterated Rating
2/5/2019	Arch Therapeutics	Roth Capital	Reiterated Rating
2/1/2019	Arch Therapeutics	Ifs Securities	Upgrade
7/24/2019	Obalon Therapeutics	Northland Securities	Reiterated Rating
4/8/2019	Obalon Therapeutics	Canaccord Genuity	Downgrade
2/25/2019	Obalon Therapeutics	Stifel Nicolaus	Upgrade
9/12/2018	Obalon Therapeutics	BTIG Research	Reiterated Rating

(Data available from 5/13/2018 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Comparison Ideas:

30 Days of MarketBeat All Access for $1.00

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your Risk-Free Trial Subscription Here

Your Ultimate Investing Toolkit

Just $1.00 for your first month.

Compare Stocks

30 Days of MarketBeat All Access for $1.00

Resources

Premium Research Tools

Market Data and Calendars

Investing Education and Resources